One-Year Data Will Support NDA for Biogen/Sage MDD Drug | BioSpace
Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea | Business Wire
Sage Therapeutics - Home | Facebook
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Thoughts
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
SAGE-217 In Major Depressive Disorder: A Multi-Center, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial
How zuranolone could change the antidepressant market
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress | Business Wire
Trial of SAGE-217 in Patients with Major Depressive Disorder | NEJM
Sage Therapeutics: Looking For Positives Ahead Of Q1 Results (NASDAQ:SAGE) | Seeking Alpha
Ο χρήστης Sage Therapeutics στο Twitter: "#Payers: Studies have found that MDD outcomes may worsen as time to remission lengthens. It's time to reevaluate how we manage #MDD #depression. See why early
The State of Depression in the U.S.
Why Early Improvement Matters
Sage Therapeutics: Steady Recovery After Biogen Deal (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress | Business Wire
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care
Biogen and Sage get August PDUFA date for oral depression drug
SY Investing on Twitter: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
Sage's depression drug improves symptoms, but durability concerns sink shares | Reuters
Trial of SAGE-217 in Patients with Major Depressive Disorder | NEJM
Depression Franchise
Sage depressed by Waterfall | Evaluate
Innovation could help address the global burden of depressive disorders
Trial of SAGE-217 in Patients with Major Depressive Disorder | NEJM
Sage-Biogen's zuranolone meets primary goal in Phase III MDD trial
Trial of SAGE-217 in Patients with Major Depressive Disorder | NEJM
